| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4   |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids |
$ Total Asks |
# Bids |
# Asks |
Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
 | Florence | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $243.44M | Series C-1A | 6/22/2022 | $10.64M | $339.88M | $11.02 | Insight Partners | ||||
 | Heal | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $174.35M | Series E | 10/21/2021 | $4.5M | $134.37M | $0.03 | Undisclosed Investors | ||||
 | HI-Bio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $22.2M | Series A | 10/20/2022 | $20M | $97.78M | $0.71 | Tom Brown, Jonas Schneider, Drew Houston, Arash Ferdowsi, Astera Institute | ||||
 | Kareo | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $136.5M | Series H | 10/9/2018 | $10M | $414.8M | $6.86 | Undisclosed Investors | ||||
 | Korro Bio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $593.6M | Series B-2 | 1/5/2022 | $45.12M | $290.4M | $2.78 | Eventide Asset Management, Fidelity, Invus, Point72, Verition Fund Management, Monashee Investment Management, Sixty Degree Capital, Atlas Venture, NEA, Wu Capital, Qiming Venture Partners, Surveyor Capital, Cormorant Asset Management, MP Healthcare Venture Management, Alexandria Venture Investments | ||||
 | Kyruus | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $192.53M | Series E | 9/15/2022 | $35.1M | $359.84M | $23.40 | Undisclosed Investors | ||||
 | Mariana Oncology | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $250M | Series B | 9/7/2023 | $175M | $311.65M | $1.06 | Deep Track Capital, Forbion, Atlas Ventures, Access Biotechnology, RA Capital Management, Nextech Invest, Surveyor Capital, Eli Lilly and Company | ||||
 | Nuvalent | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $187.23M | Series B | 5/11/2021 | $135M | $461.14M | $11.14 | Bain Capital Life Sciences, Deerfield Management, Fidelity, Wellington Management, Viking Global Investors, Janus Henderson Investors, Avoro Capital, Boxer Capital, Venrock, Fairmount Funds Management, Driehaus Capital Management, Logos Capital | ||||
 | PatientPop | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $125.82M | Series C | 8/25/2020 | $42.65M | $425.93M | $9.93 | HLM Venture Partners, Commonfund, Vivo Capital, Toba Capital, Transformation Capital, Silicon Valley Bank | ||||
 | Pyxis Oncology | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $194.5M | Series B | 3/30/2021 | $172.5M | $273.43M | $10.47 | Arix Bioscience, RTW Investments, Perceptive Advisors, RA Capital Management, Pfizer Ventures, BVF Partners, Janus Henderson Investors, Cormorant Asset Management, HBM Healthcare Investments, Tekla Capital Management, Acuta Capital Partners, Ridgeback Capital Investments, Surveyor Capital, Laurion Capital Management, Logos Capital, LifeSci Venture Partners, Leaps by Bayer, Agent Capital, Ipsen Ventures, Longwood Fund, 3E Bioventures | ||||
 | ROME Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $199M | Series B | 9/24/2021 | $149M | $321.94M | $1.49 | Johnson & Johnson Innovation, Bristol Myers Squibb, Eurofarma Ventures, Luma Group, Mirae Asset Capital, Raycap, Sigmas Group, ARCH Ventures, GV, Section 32, Sanofi Ventures, Andreessen Horowitz, Mass General Brigham Ventures, Casdin Capital, Alexandria Venture Investments | ||||
 | Santa Ana Bio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $168.34M | Series B-2 | 6/13/2024 | $62.5M | $264.43M | $1.50 | Versant Ventures, TPG, GV, Access Biotechnology, Andreessen Horowitz, RTW Investments | ||||
 | Svelte Medical Systems | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $153.65M | Series C | 4/23/2021 | $11.89M | $396.2M | $321.83 | Undisclosed Investors | ||||
 | Taiga Biotechnologies | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $42.83M | Series C | 5/31/2019 | $27.2M | $442.88M | $6.80 | Undisclosed Investors | ||||
 | Tango Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $166.88M | Series B-1 | 8/17/2020 | $51.18M | $305.79M | $1.89 | Casdin Capital, Boxer Capital, Cormorant Asset Management, Gilead Sciences | ||||
 | Tetherex Pharmaceuticals | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $68.65M | Series B | 4/18/2018 | $63.95M | $366.68M | $21.32 | MPM Capital, Philip Jones | ||||
 | Theracos | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $135.86M | Series C | 9/20/2013 | $93.09M | $327.39M | $18.62 | Undisclosed Investors | ||||
 | Third Arc Bio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $197.75M | Series A | 7/16/2024 | $165M | $305.43M | $2.10 | Vida Ventures, Cormorant Asset Management, Hillhouse Investment, Omega Funds, Goldman Sachs, BVF Partners, T. Rowe Price Associates, Janus Henderson Investors, abrdn, Marshall Wace, Foresite Capital, Logos Capital, Freepoint Capital Group, AbbVie Ventures | ||||
 | Tizona Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $95.24M | Series B-3 | 1/3/2019 | $15M | $173.78M | $1.60 | AbbVie | ||||
 | Apexigen | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $165.38M | Series C | 3/24/2020 | $127.86M | $343.82M | $1.55 | Decheng Capital, Oceanpine Capital, 3E Bioventures Capital, VI Ventures, SV Tech Ventures, H&Q Asia Pacific, LDV Ventures, ShangBay Capital, Delian Capital, Hua Nan Venture Capital, Efung Capital | ||||
 | AZTherapies | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $121.38M | Series C-1 | 8/28/2020 | $35M | $401.38M | $6.75 | Duopharma Biotech Berhad, Spinnaker Capital, ID Fund, DRADS Capital, Wexford Capital, Nextrans-KCLAVIS, Axiom Associates, DEFTA Partners | ||||
 | Centrexion Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $569.49M | Series D | 9/30/2019 | $90.34M | $327.06M | $1.80 | New Enterprise Associates, Eli Lilly, Exome Asset Management, Quan Capital, ArrowMark Partners, Clough Capital Partners L.P., InterWest Partners, 6 Dimensions Capital, Efung Capital | ||||
 | Cue Health | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $179.56M | Series C-1 | 6/10/2020 | $100M | $455.86M | $3.66 | Decheng Capital, Foresite Capital, Madrone Capital Partners, Johnson & Johnson Innovation, ACME Capital | ||||
 | Elektrofi | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $284.44M | Series C | 8/8/2024 | $96.45M | $402.83M | $14.04 | Undisclosed Investors | ||||